glp-1 substance use disorder GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though GLP-1 drugs protect against new

Many people turn to skin-brightening creams or serums to improve their complexion but these topical solutions often fall short

The FDA issued guidance stating that 503A compounding pharmacies had until April 22, 2025 to stop producing semaglutide injection products that were essentially copies of the commercially available drug

USA 101 , 1650116506 (2004)

Endocrine disrupting chemicals: effects on endocrine glands

More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/2026 1 , while around 2.5 million people each month accessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of the Digital Clinical Excellence (DiCE) network of primary care digital health providers